X4 Pharmaceuticals (XFOR) investor relations material

Company overview and business model

• Focuses on developing and commercializing novel therapeutics for rare hematology diseases, aiming for profitability through product development and commercialization, independently or with partners.

• Main asset is mavorixafor, an oral CXCR4 antagonist, with FDA-approved XOLREMDI® for WHIM syndrome and ongoing pivotal Phase 3 trial (4WARD) for chronic neutropenia.

• Incorporated in Delaware, with headquarters in Boston, and operates as a smaller reporting company under SEC rules.

Financial performance and metrics

• As of March 31, 2026, 94,319,696 shares of common stock were outstanding, with a net tangible book value of $1.49 per share.

• After a $75 million offering at $4.21 per share, as adjusted net tangible book value would be $1.90 per share, resulting in immediate dilution of $2.31 per share to new investors.

• Additional outstanding options, warrants, and restricted stock units could further dilute shareholders.

Use of proceeds and capital allocation

• Proceeds will be used to advance ongoing and planned clinical trials, develop additional product candidates, and for working capital and general corporate purposes.

• Management retains broad discretion over the use of funds, with no specific commitments to acquisitions or licensing at this time.

• Pending use, proceeds may be invested in capital preservation instruments.